Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merz

Daiichi Sankyo logo

Japan’s Daiichi Sankyo pays $410m for Ambit Biosciences

Gains rights to cancer drug quizartinib

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

FDA approves Lilly’s GLP-1 diabetes drug Trulicity

The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza

- PMLiVE

NHS ‘not driving’ health innovation

Minister for Life Sciences acknowledges UK has more to do

Eli Lilly HQ

Lilly closes in on another Cyramza indication

Could be used for colorectal cancer in addition to stomach cancer

EU flag

Lantus faces first biosimilar rival in Europe

Sanofi prepares for insulin challenge from Boehringer and Lilly

- PMLiVE

ABPI-backed study causes Servier Code of Practice breach

Company failed to disclose study results in suitable time

- PMLiVE

Lilly says peglispro tops Lantus in diabetes trials

New insulin demonstrates superiority to Sanofi’s product in cutting blood sugar levels

- PMLiVE

HCA names new chief executive

Anneliese Cameron will take over from Julia Cook in January

- PMLiVE

Lilly’s psoriasis candidate tops Enbrel in phase III trials

Ixekizumab on course for regulatory filing in first half of 2015

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

- PMLiVE

Boehringer/Lilly’s Jardiance approved in US

But the FDA wants four post-marketing studies of the SGLT-2 diabetes drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links